inotuzumab ozogamicin,blinatumomab
pfizer,amgen,ucb pharmaceuticals
['leusm', 'blina ', 'inotuzumab', 'inotuzumab ozogamicin']
congress #eha2023 | matthew wieduwilt describes chemo-free therapy with inotuzumab ozogamicin+blina for older pts with b-all. n=33. cumulative cr rates through induction ia-c &amp; composite =85% &amp; 96%, respectively. with median fu of 22 mo, the 1-yr efs =75% #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm